Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial. (PubMed, Lancet Respir Med) - Jul 8, 2026 - P1/2, P3 | "The dual-oral chemotherapy-free regimen of ifebemtinib plus garsorasib had encouraging efficacy with a manageable safety profile as first-line treatment for KRASG12C-mutated NSCLC. A randomised phase 3 study has been initiated to further validate these findings against standard-of-care in the first-line setting (NCT07174908)."
Journal • P1/2 data • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Hypertension • Infectious Disease • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pneumonia • Renal Disease • Respiratory Diseases • Solid Tumor • KRAS
|
|
Huaqiu Shi; Liming Zhu; Ling Zhang; Rongbo Lin; Tangfeng Lv; Xingya Li; Ying Liu; Yinxin Zhu; Yiping Zhang; Yongzhong Luo; Yuan Yuan; Zaiqi Wang; Zhengbo Song
|